Glimepiride and Metformin Fixed-Dose Combination (FDC) along with Metformin + Dapagliflozin + Sitagliptin FDC in T2DM Patients with High Risk for Cardiovascular Disease: GRACE-CVD Study
Journal of Diabetology · 2026-05 · 17 (3) · 243-249
DOI: 10.4103/jod.jod_142_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetology, online erschienen am 22.05.2026. Verfasst von L. S. Murthy und 9 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Cardiovascular complications are a major cause of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). Fixed-dose combinations (FDCs) of antidiabetic agents may improve glycemic control, cardiovascular outcomes, and treatment adherence. However, real-world evidence in high cardiovascular risk settings is limited.
Objective
The GRACE-CVD study evaluated the effectiveness, tolerability, and physician-reported outcomes of dual FDC (Metformin + Glimepiride) and triple FDC (Metformin + Dapagliflozin + Sitagliptin) in T2DM patients with established or high cardiovascular disease (CVD) risk. Materials and Methods: This retrospective, multicenter study analyzed 1772 adult T2DM patients from 150 Indian centers. Patients had either established CVD or high CVD risk. Key parameters, including HbA1c, fasting and postprandial blood glucose, blood pressure, lipid profile, renal function, weight, and adverse events, were assessed over an average follow-up of 4.1 ± 3.1 months. Adherence, satisfaction, and reasons for prescribing FDCs were also captured.
Results
Both FDC regimens significantly improved glycemic outcomes, with HbA1c of
Zitieren
APA
Murthy, L. S., Jain, A., Katakam, L., Bhattacharyya, A., Sait, K. N., Chavan, M., Chitale, M., Bhojane, S., Sardar, A., & Prasad, A. (2026). Glimepiride and Metformin Fixed-Dose Combination (FDC) along with Metformin + Dapagliflozin + Sitagliptin FDC in T2DM Patients with High Risk for Cardiovascular Disease: GRACE-CVD Study. Journal of Diabetology, 17(3), 243-249. https://doi.org/10.4103/jod.jod_142_25
Vancouver
Murthy LS, Jain A, Katakam L, Bhattacharyya A, Sait KN, Chavan M, et al. Glimepiride and Metformin Fixed-Dose Combination (FDC) along with Metformin + Dapagliflozin + Sitagliptin FDC in T2DM Patients with High Risk for Cardiovascular Disease: GRACE-CVD Study. Journal of Diabetology. 2026;17(3):243-249. doi:10.4103/jod.jod_142_25
BibTeX
@article{Murthy2026,
author = {Murthy, L. S. and Jain, Anuj and Katakam, Lavanya and Bhattacharyya, Arpandev and Sait, K. N. and Chavan, Mahesh and Chitale, Manoj and Bhojane, Sonali and Sardar, Ashish and Prasad, Ashish},
title = {Glimepiride and Metformin Fixed-Dose Combination (FDC) along with Metformin + Dapagliflozin + Sitagliptin FDC in T2DM Patients with High Risk for Cardiovascular Disease: GRACE-CVD Study},
journal = {Journal of Diabetology},
year = {2026},
volume = {17},
number = {3},
pages = {243--249},
doi = {10.4103/jod.jod_142_25}
}
EUVIMED